XRCC2 and brain cancer: As shown in Figure 2A, within subtypes of brain cancer, the top three mutation rates were MAD2L2/FANCV (21.49%) in meningioma, XRCC2/FANCU (17%) in rhabdoid tumors, and ATM (16%) in pediatric high-grade gliomas.